Physician profile
Mark J Friedman
NPI 1104018050
$374.03
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $333 · 2022: $41.12.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $105.94 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $83.81 | 2021-2022 | |
| Alkermes, INC. | $48.99 | 2021 | |
| Lundbeck LLC | $34.03 | 2021 | |
| Vanda Pharmaceuticals INC. | $28.07 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $27.48 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $17.78 | 2021 | |
| Uswm, LLC | $16.08 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $11.85 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Friedman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.